Treatment of Multiple Myeloma - Patent Overview (Last 5 years)
Multiple myeloma is cancer formed by malignant plasma cells. Normal plasma cells are found in the bone marrow and are an important part of the immune system. In multiple myeloma, a type of white blood cell called a plasma cell multiplies unusually. Normally, they make antibodies that help fight infections.But in multiple myeloma, they release too much protein (called immunoglobulin) into the bones and blood. It builds up throughout the body, causing organ damage.The plasma cells also crowd normal blood cells in the bone. They release chemicals that dissolve bone. The weak areas of bone created by this are called lytic lesions.As multiple myeloma gets worse, those plasma cells begin to spill out of the bone marrow and spread through the body. This causes more organ damage.
Dasatinib can be administered alone or in combination with a second anti-neoplastic agent such as dexamethasone or bortezomib for the treatment of multiple myeloma. This is claimed in one of the patents by Stragen Pharma S.A.. There are lots of improvements which led to lot more patents in the recent years and to know more it is worth going through the patent overview report.
This patent report provides a statistical overview of the specified technology/segment for the last five years.The claimed technology in the patent is segmented categorically and is the basis for insights into research and business.The report focuses on IP publication trends and the top 20 assignees - their technology trends and research breadth across various jurisdictions. The ‘White Space Matrix’ across major categories is a fundamental part of this Patent Overview Report.
Who can use the report?
Helps in mapping the big players in the broad spectrum of the technology
Helps in digging out white spaces that identify the technology gaps
Cognizant about the chronological developments in the technological field for the last 5 years
Finding alternative technical solutions to a problem
Helps in knowing the innovative focus of companies, industries, and countries
Spotting the new competitors
Legal assessors and representatives
Filing trends either for the overall number of patents, or just for certain groupings in the last 5 years
Financial and fiscal assessors and representatives
Forms the base for the evaluation of patents within the context of the control of organizational resources and accounting